XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Revenue REVENUEThe Company develops, manufactures and sells devices designed primarily for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and blocking pain by temporarily ablating peripheral nerves. These devices are developed and marketed to a broad base of medical centers globally. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.
United States revenue by product type is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Open ablation $22,070$19,503$41,044$36,942
Minimally invasive ablation 10,1549,70218,76918,087
Pain management10,2105,70918,2249,607
Total ablation$42,434$34,914$78,037$64,636
Appendage management28,83125,15655,50045,743
Total United States$71,265$60,070$133,537$110,379
International revenue by product type is as follows:
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2022202120222021
Open ablation $6,213$5,526$12,705$9,960
Minimally invasive ablation 1,2711,5752,8042,849
Pain management1141125411
Total ablation$7,598$7,112$15,763$12,820
Appendage management5,6664,1949,8057,452
Total International $13,264$11,306$25,568$20,272
Revenue attributed to customer geographic locations is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
United States$71,265$60,070$133,537$110,379
Europe7,7837,01515,02012,781
Asia4,9334,0889,4906,961
Other International5482031,058530
Total International13,26411,30625,56820,272
Total Revenue$84,529$71,376$159,105$130,651